Why no country wants to access the European Stability Mechanism. The example of Italy.

Bonds

Althea Spinozzi

Fixed Income Strategist

Summary:  The European Stability Mechanism (ESM) is an obsolete facility that endangers the sovereignty of European Union members. Dilution risk, a rise of government funding costs and stigma are some of the threats a country runs into for getting cheap financing. We find that European countries are better off raising money in the capital market rather than applying for a loan to the ESM.


The European Stability Mechanism split people's opinion. The argument that many make it's straightforward: the ESM provides cheap loans, hence why shouldn't European members take advantage of it? Well, the issue here is that the ESM is not a charity institution giving out loans to needing countries. The ESM is lucrative, precisely like a bank, and it gives out cheap loans in exchange of fees and economic commitments.

How does the ESM works

To understand why European countries are deciding not to access this facility, it is necessary to know how the ESM works and what is written in the loans' footnotes.

Firstly, the ESM facility gives out loans only for Covid-19 related expenditures, which have already incurred. It means that a country needs to increase its fiscal deficit first, then it will be able to request a loan.

Secondly, the maximum amount that a country can request is up to 2% of 2019 GDP[1]. In the case of Italy, last year’s GDP was around €1.8 trillion; hence the country could apply for approximately €36bn to the ESM. Italy will not receive this money on one go; the ESM will dilute disbursements over several months as the debtor can obtain only up to 15% of the overall amount at the time. Hence, for Italy, it will take around seven months to get the full amount.

The country will not be able to ask the ESM for the full €36bn because it didn’t spend that amount for the Covid-19 emergency. According to the Ministry of Economy and Finance, Italy has so far allocated €9.5bn[2] to strengthen the health care system in light of the Coronavirus pandemic. On top of it, the budget for the National Health Services in 2019 was around €114bn[3]. Hence, it will be hard for Italy to justify that 30% of its health budget comes solely from Covid-19 related expenses.

Why it doesn’t make sense to access the ESM facility when a country can finance itself in the capital market

ESM’s loans are incomparable to sovereign debt precisely for the same reason why you wouldn't compare the cost of your mortgage to the cost of your car loan. Below I explain what is the difference is between the two and why it is preferable to finance government deficit directly from the market.

  • ESM loans are senior to sovereign creditors[4]. This brings dilution risk, which can negatively affect the debt structure of the country that taps into the facility. In practice, this means that to get just €9 bn Italy has to give priority over its obligation to the ESM before any other creditor holder of its sovereign debt. This leads to a change in the country's debt repayment structure which will force sovereign creditors to demand more yield as they have now privileged creditors before them. Hence, the tradeoff to get €9bn cheap from the ESM causing a repricing of €2 trillion worth in Italian government bonds is not only expensive, but it is also damaging. To put it in numbers, lets assumes that Italy saves 80bps over a €36bn loan. The total saving is of €288mil. However, BTP creditors now demand 2 more basis point over €2tr sovereigns, this will potentially cost the country around €400mil.

  • The ESM imposes conditionality; sovereign debt doesn't. This is a pretty huge point. The borrowing country will need to be placed under special surveillance in order to secure repayment. The ESM will enforce economic and fiscal conditions to ensure that the loan will be repaid. The same doesn't happen when a country raises money with government bonds.

  • The interest rate on ESM loans is variable, and it depends on the funding strategy of the facility. As we explained in an earlier article, Spain borrowed from the ESM at a lending rate of 40bps in 2013, but it ended up paying 100bps in 2014 as the funding strategy of the ESM shifted from issuing short term to long term securities[5]. When issuing BTPs, Italy can choose a convenient maturity and its cost of funding which is something it will no be able to do with the ESM.

  • Accessing the ESM will mean declaring that the country is in financial instability, which gives an entirely wrong picture of the Italian situation. Italy can access the capital markets without problems and has no funding issues.

In conclusion, it is wrong to compare ESM loans pricing with sovereign yields because they are not comparable. The only way to appreciate the convenience of the ESM is to compare it to the price of a syndicated loan with seniority over the BTPs .

The price of that loan will certainly be lower compared to BTP yields. And even though it will not be as cheap as accessing to the ESM, a country would rather pay more than paying the cost of stigma.

Right now, Italy can finance itself at the lower interest rates the country has ever seen in history. At the moment of writing, the country benefits of negative interest rates for 3-year maturities, while it pays only 12bps for 5-year debt. Yesterday, the country issued €8bn 30-year BTPS in a blink of an eye, with books reaching €90bn in demand. It definitively doesn't look like a country on the brink of default; actually, it's drowning liquidity.

Within this context, ESM financing looks very much like Snow White's apple: perfectly round and red but poisoned. Don't get me wrong. I am at core a firm believer and supporter of the European Union. However, it is clear that the ESM is an outdated tool created for countries in financial distress in the high of the 2012 banking crisis.

Suppose the European counterparties really want to provide cheap financing to countries that are incurring rising Covid-19 related expenses. In that case, they should rethink the ESM framework. If, for example, the ESM was to accept pari-passu status with sovereign creditors, this would resolve many things. However, the issues related to the stigma will continue to weight on a country's cost of funding, making the ESM still unviable.

With the second wave of coronavirus hitting Europe, the EU might not have an alternative rather than issuing joint debt instruments and get rid of such obsolete frameworks.

 


[1] https://www.consilium.europa.eu/media/44011/20200508-pcs-term-sheet-final.pdf

[2] https://www.mef.gov.it/covid-19/Sanita-e-Protezione-Civile/

[3] http://www.salute.gov.it/portale/temi/p2_6.jsp?id=4752&area=programmazioneSanitariaLea&menu=d

[4] Paragraph 6.2.1,b.; https://www.esm.europa.eu/sites/default/files/general_terms_15122015_clean.pdf

[5] https://www.esm.europa.eu/lending-rates

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide and Product Disclosure Statement to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as CFDs and Margin FX products may result in your losses surpassing your initial deposits. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.
Please click here to view our full disclaimer.